Long COVID affects a significant portion of people who have had COVID-19, with estimates suggesting that between 10% and 30% of patients develop persistent symptoms lasting months or even years after infection1 . This condition poses a major public health challenge due to its complex symptoms and impact on quality of life2 . Understanding the key predictors of long COVID can help identify individuals at higher risk and guide prevention and treatment strategies3 .
Defining Long COVID
Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), is a chronic condition characterized by symptoms that persist or relapse beyond the acute phase of COVID-19 infection, typically lasting more than 12 weeks4 5. It is a multisystem illness with a wide range of symptoms affecting respiratory, neurological, and psychological domains6 4. Common symptoms include fatigue, shortness of breath, cognitive impairment (often called brain fog), sleep disturbances, and changes in taste or smell6 47.
The prevalence of long COVID varies widely depending on study design, population, and viral variant, with some systematic reviews reporting that 21% to 74.5% of COVID-19 patients experience at least one persistent symptom8 9. Population-based studies estimate that about 10% to 30% of patients develop long COVID symptoms2 10. The condition affects people of all ages, including children and adolescents, and can occur even after mild or asymptomatic infections11 3.
Long COVID is not a single disease but an umbrella term encompassing multiple distinct clinical presentations and underlying mechanisms12 . Symptoms may fluctuate over time, making diagnosis and management challenging7 . There is currently no definitive laboratory test for long COVID; diagnosis relies on clinical history, symptom patterns, and exclusion of other causes3 .
Key Long COVID Predictors
Research has identified several factors that increase the likelihood of developing long COVID. These predictors include biological markers, viral factors, and patient characteristics. Understanding these can help clinicians identify at-risk individuals and tailor interventions.
Autoantibodies
One of the emerging biological predictors of long COVID is the presence of autoantibodies—antibodies that mistakenly target the body’s own tissues. Studies have found that approximately two-thirds of patients who develop long COVID have detectable autoantibodies at the time of their initial COVID-19 diagnosis13 14. Higher levels of these autoantibodies correlate with a decreased level of protective SARS-CoV-2 antibodies, suggesting a dysregulated immune response13 .
Autoantibodies may contribute to persistent symptoms by triggering autoimmune reactions that damage various organs or tissues. Early detection of these autoantibodies could serve as a biomarker to predict who is at greatest risk for long COVID and may guide early therapeutic interventions using immunomodulatory treatments13 14.
Additionally, research from University Hospital Zurich identified that low levels of certain antibodies, such as IgM (the first antibody produced in response to infection), were more common in individuals who developed long COVID compared to those who recovered quickly. Combining antibody profiles with clinical data like age and pre-existing asthma allowed prediction of moderate to very high risk for persistent symptoms14 .
Epstein-Barr Virus (EBV)
Another important predictor is the reactivation of latent viruses, particularly Epstein-Barr virus (EBV). EBV infects about 90% of the global population and usually remains dormant after initial infection. However, studies have shown that EBV can reactivate early after SARS-CoV-2 infection, and this reactivation is significantly associated with the development of long COVID symptoms13 14.
The immune response to COVID-19 may disturb the balance that keeps EBV inactive, leading to its reactivation and contributing to ongoing symptoms such as fatigue, neurological issues, and immune dysregulation. This finding suggests that antiviral therapies targeting EBV might be a potential avenue for treating certain long COVID cases13 .
Psychological distress before COVID-19 infection may increase the risk of developing long COVID, although further research is needed to confirm this link26 .
Other factors
Beyond autoantibodies and EBV, several other factors have been linked to increased risk of long COVID:
-
Sex: Women have consistently been found to have higher odds of developing long COVID compared to men, especially in middle age (40–50 years), possibly due to differences in immune response and higher prevalence of autoimmune diseases among females15 1614.
-
Age: Older age is associated with greater risk, with people over 70 years reporting more persistent symptoms. However, some studies suggest that long COVID is most prevalent in mid-life adults (35–69 years) 21417.
-
Severity of initial illness: Patients who experienced severe or critical COVID-19 illness, including hospitalization or intensive care, are more likely to develop long COVID18 163.
-
Pre-existing conditions: Chronic diseases such as cardiovascular disease, diabetes, asthma, and depression increase the risk of long COVID19 1514.
-
Multiple symptoms early in infection: Experiencing more than five symptoms during the first week of COVID-19 illness raises the likelihood of persistent symptoms by 3.5 times14 .
-
Viral load: Higher amounts of virus during early infection correlate with increased risk of long COVID14 .
-
Socioeconomic and ethnic factors: Minority ethnic status and socioeconomic disadvantage have been linked to higher incidence of long COVID, likely reflecting health inequities20 10.
The presence of autoantibodies and reactivation of latent viruses like EBV are key biological factors linked to long COVID, opening new avenues for potential treatments13 14.
- Vaccination status: COVID-19 vaccination prior to infection reduces the risk of developing long COVID2 153.
These factors highlight the multifaceted nature of long COVID risk, involving immune, viral, demographic, and social determinants.
- Risk Factors for Long COVID:
- Female sex, especially ages 40–5014 17
- Older age, particularly over 702 14
- Severe initial COVID-19 illness18 16
- Pre-existing chronic diseases (cardiovascular, diabetes, asthma, depression) 191514
- Multiple early symptoms (>5 in first week) 14
- High viral load during infection14
- Socioeconomic disadvantage and minority ethnicity20 10
- Lack of COVID-19 vaccination2 153
“It’s the first real solid attempt to come up with some biologic mechanisms for long COVID.”
— Dr. Steven Deeks, University of California, San Francisco13
Implications for Long COVID Patients
Long COVID remains a significant clinical and public health challenge due to its complex, multisystem nature and variable symptom patterns21 6. The heterogeneity of symptoms necessitates multidisciplinary care models that address physical, neurological, and psychological needs22 .
Vaccination is the best available tool to prevent long COVID, reducing both the risk of infection and the likelihood of persistent symptoms if infected3 . Early antiviral treatment during acute infection may also help mitigate long COVID risk by reducing viral replication12 .
Patients with long COVID often face difficulties in diagnosis and management due to fluctuating symptoms and lack of definitive tests7 . Comprehensive clinical evaluations and personalized treatment plans are essential. Symptom management may include:
Long COVID symptoms can be unpredictable, fluctuating in intensity and type over time, which complicates diagnosis and treatment. Vaccination and early antiviral therapy remain critical strategies to reduce the burden of long COVID12 243.
- Graded physical activity to manage fatigue without exacerbation7
- Medications for pain, breathlessness, or heart rate abnormalities such as postural orthostatic tachycardia syndrome (POTS) 7
- Olfactory training for loss of taste or smell7
- Psychological support for mood and cognitive symptoms7
Ongoing research initiatives like the NIH RECOVER Initiative are working to better understand long COVID’s mechanisms, identify biomarkers, and develop targeted therapies19 2324. Clinical trials are exploring repurposed drugs tailored to specific underlying causes, such as antivirals for persistent viral reservoirs, immunomodulators for inflammation, and therapies for autoimmune components12 .
Health inequities contribute to disparities in long COVID diagnosis and care, emphasizing the need for equitable access to healthcare and support services20 10. Patient-centered approaches and integrated healthcare models are recommended to address the diverse needs of long COVID patients25 22.
- Key management considerations for long COVID patients:
- Multidisciplinary care addressing physical, neurological, and psychological symptoms22
- Early vaccination and antiviral treatment to reduce risk12 3
- Personalized symptom management plans7
- Addressing health inequities to improve access to diagnosis and care20 10
- Continued research to develop targeted therapies and biomarkers19 2324
